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Background and the purpose of the study: Boswellia carterii have been used in traditional medicine for many
years for management different gastrointestinal disorders. In this study, we wish to report urease inhibitory activity
of four isolated compound of boswellic acid derivative.
Methods: 4 pentacyclic triterpenoid acids were isolated from Boswellia carterii and identified by NMR and Mass
spectroscopic analysis (compounds 1, 3-O-acetyl-9,11-dehydro-β-boswellic acid; 2, 3-O-acetyl-11-hydroxy-β-boswellic
acid; 3. 3-O- acetyl-11-keto-β-boswellic acid and 4, 11-keto-β-boswellic acid. Their inhibitory activity on Jack bean
urease were evaluated. Docking and pharmacophore analysis using AutoDock 4.2 and Ligandscout 3.03 programs
were also performed to explain possible mechanism of interaction between isolated compounds and urease
enzyme.
Results: It was found that compound 1 has the strongest inhibitory activity against Jack bean urease
(IC50 = 6.27 ± 0.03 μM), compared with thiourea as a standard inhibitor (IC50 = 21.1 ± 0.3 μM).
Conclusion: The inhibition potency is probably due to the formation of appropriate hydrogen bonds and
hydrophobic interactions between the investigated compounds and urease enzyme active site and confirms its
traditional usage.
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Inhibition of enzymes by natural products which are
proven to be the source of therapeutic agents, have in-
creasingly attracted the interests of scientists as a valu-
able strategy in drug discovery. Boswellia carterii is
widely distributed in the Indian subcontinent and Africa.
The gum exudates of Boswellia spp. comprise of several
pentacyclic triterpenoid acids, which are known as
boswellic acids (BA’s) and reported to have different bio-
logical activities. Their ability to induce apoptosis choose
them as potent compounds in treatment of colon, pros-
tate and breast cancers [1-7] and a broad range of neu-
rodegenerative conditions such as Alzheimer’s and
Parkinson’s disease [8-11]. Also their inhibitory effect
through topoisomerase I and II has been reported [12].* Correspondence: amanlou@tums.ac.ir
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reproduction in any medium, provided the orIn addition, a number of extracted organic acids of this
plant show other biological activities such as inhibition
of peptic ulcer formation, probably by increasing the
gastric mucosal resistance which its exact molecular
mechanism is still not clear. In the recent report, it was
shown that methanolic extract of B. carterii has urease
inhibition activity [13,14].
Enzyme inhibition has already led to the discovery of
the wide variety of useful drugs in the treatment of sev-
eral diseases. It is found that Helicobacter pylori infec-
tion is the main cause of gastritis, peptic ulcer disease
and gastric cancers [15,16].
Urease of H. pylori producing abundant amounts of
ammonia (10–15% of total proteins by weight), make the
growth and survival of bacteria possible, by increasing
the pH of environment [17]. Therefore, it plays the
major role in gastric diseases. Accordingly, urease inhib-
ition has recently attracted much attention in pharma-
ceutical applications and discovery of potent anti-ulcerral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tics, thus introducing new agents, like natural urease
inhibitors, is of special importance. In addition, urease
activity not only participates in the formation of kidney
stones [18], but also involves in the development of uro-
lithiasis, pyelonephritis, hepatic encephalopathy [19].
Throughout our work to search for natural urease
inhibitor’s compounds from medicinal plants, we now
report the isolation of four derivatives of boswellic acids
to test their inhibitory activities through Jack bean
urease. We employed Jack bean urease instead of bacter-
ia’s one because it was previously found out that the
mechanism and kinetics of inhibition for bacteria urease
and Jack bean urease are comparable [20].
Molecular docking and simulation studies improve the
reliability, accuracy of biological test, and show possible
interactions between molecules and their target recep-
tors. So the extracted compounds were subjected to
molecular docking for better recognition of their inter-
action with urease.
Material and methods
Materials
Jack bean urease (EC 3.5.1.5 from Fluka Co, Switzerland),
thiourea and all other chemicals used were of analytical
grade (Merck Co, Germany). All solutions were prepared in
MilliQ (Millipore, USA) water.
Preparation of extract
An earlier report claimed that acetyl-keto-β-boswellic
acid could not be separated from a mixture of acetyl-β-
boswellic acid and acetyl keto-β-boswellic acid by any of
the chemical methods, such as ketal formation [21] or
semi-carbazide formation. In another method, methanol
was found to be the most appropriate solvent for extrac-
tion, and used for simultaneous quantitative estimation
of major BA’s from Boswellia spp.
In this research, solvent-solvent extraction, thin-layer
(TLC) and column chromatography were performed to iso-
late the main active constituent of B. carterii. A total of
10 g of oleo-gum resin was grounded. Of this, extractionFigure 1 Structure of isolated boswellic acid derivatives.performed in 100 ml methanol three times. After filtration,
the extract was concentrated and solvent was removed.
KOH 2% was added to separate the acidic fraction and ex-
traction was performed by ethyl acetate five times. In the
next step, the aqueous phase was acidified with HCl 2%,
and previous step was repeated. Then the organic phase
washed with distilled water to obtain fractions containing
BA’s compounds. Liquid chromatography was used to ob-
tain related derivatives in organic fraction. The organic
layers were dried, filtered and concentrated under vacuum
on a rotary evaporator. Liquid chromatography of 5 g of
sample which dissolve in chloroform is performed on 100 g
of silica gel 60 (0.063 - 0.2 mm). Solvent partitioning of the
crude extracts was used to divide the extract into eight frac-
tions with different polarities. The fractions were combined
based on similarity of the chemical composition deter-
mined by TLC analysis.
Crude fractions 1-5 were concentrated under vacuum on
the rotary evaporator. Fractions 6-7 were combined based
on similarity of their TLC profile and subjected to further
column chromatography and eluted with a methanol/
chloroform gradient solvent mixture (3; 5; 7; 10ml of
methanol) to give fractions K, L, M and O. pure compound
was identified using spectroscopic analysis which their
structures are shown in Figure 1. The 1H and 13C-NMR
spectra were recorded on a Bruker Avance 300-MHz NMR
spectrophotometer, with internal standard tetramethylsilane
(TMS). The structures were further confirmed by mass-
spectral analysis and comparing with reported data for all
the compounds.Biological evaluation
For urease inhibition assays after addition of phosphate
buffer pH = 6.8, sonication was performed for 3 min, fol-
lowed by centrifugation and evaluating absorbance of
upper solution in λ = 278 nm which is attributed to the
urease. By using following equation A = λbc, where c is
the concentration of solution (mol/L), b the Length of
the UV cell, we can calculate the concentration of ini-
tially urease solution in this way. After appropriate
Table 1 Percent of inhibition, IC50 and ΔGº of four
isolated boswellic acids derivatives
Compounds Percent of inhibition IC50 ± S.E.M ΔGº
(50 μg/ml) (μM) (Kcal/mol)
1 60.5 6.27 ± 0.037 −7.49
2 56.2 9.21 ± 0.069 −7.20
3 37.4 16.34 ± 0.063 −7.11
4 39.1 85.23 ± 0.065 −5.84
Thiourea 88.0 21.10 ± 0.3 −6.42
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2 mg/ml.
The assay mixture, containing 50 μl (2 mg/ml) of
Jack-bean urease and 100 μl of different concentration
of test compounds, which were dissolved in ethanol
20% previously, was added to 850 μl of 25mM urea and
pre-incubated for 0.5 h in water bath at 37°C. The
urease reaction was stopped after 30 min incubation by
following procedure.
Urease activity was determined by measuring ammonia
production using the indophenol method as described by
Weatherburn [18]. After pre-incubation, 500 μl of phenol
reagent (1% w/v phenol and 0.005% w/v sodium nitroprus-
side) and 500 μl of alkali reagent (1% w/v NaOH and
0.075% active chloride NaOCl) were added to 100 μl of in-
cubation mixture and kept at 37°C for 30 min.
The absorbance was measured at 625 nm. All experi-
ments were performed in triplicate in a final volume of 1
ml, and thiourea was used as a standard urease inhibi-
tors. Percentage inhibitions were calculated using the
formula (100 – (OD sample / OD control) × 100).
The concentration that provokes an inhibition halfway
between the minimum and maximum response of eachFigure 2 Molecular docking of compound 1, a 3D aspect.compound (relative IC50) was determined by monitoring
the inhibition effect of various concentrations of com-
pounds in the assay. The IC50 values were then calcu-
lated using GraphPad Prism 5 software.
Molecular docking
The newly compounds were subjected for molecular
docking. To validate observed activities and designing
new inhibitors based on choosing the appropriate
pharmacophore molecular docking was performed using
AutoDock 4.2 along with AutoDockTools 1.4.5 using
Lamarckian genetic algorithm on PDB structure (3LA4)
http://www.pdb.org with resolution of 2°A [22].
In the present study, non-standard protein residues
(KCX and CME) and the metal ions were included in
the binding site specification. The docking calculations
adopted in this work yield favorable orientations of
ligands in a receptor. The graphical user interface ADT
was employed to set up the enzymes: all hydrogen calcu-
lated and nonpolar hydrogens were merged to carbons.
For determination of pharmacophore, Ligandscout 3.03
program was used [23].
Four potent inhibitors have sketched by Marvin sketch
applet (Marvin package, Chemaxon company). Then
adding polar hydrogens and rotatable bonds were
done with Openbabel and AutodockTools, respectively
[24,25]. Docking with a maximum number of 25 × 106
energy evaluations were performed. After clustering ana-
lysis, conformation with the most favorable binding en-
ergy was selected.
Result and discussion
Plants are the important source of new drug develop-
ments. Current study presents an investigation on urease
Figure 3 Molecular docking of compound 1 and its interaction
with different residue of urease enzyme active site involved in
interaction. Formation of hydrogen bonds between carbonyl of
Phe 569, Ser 567, Ile 568 and Lys 445 from B-domain of enzyme and
oxygen of the carboxyl moiety in compound 1. Hydrophobic
interactions with Ala 150, Leu 457, Try 474 and Try 475 of urease.
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which has been numbered as medicinal plant and had
been used in stomach and colon disorders [26,27], on
the other hand, detection of urease inhibitors, have been
regarded as targets for new anti-ulcer drugs.Figure 4 Molecular docking of compound 2 and its interaction with d
interaction.The aim of the present study is to confirm the possible
anti-ulcer activity of the olibanum through inhibition of
urease enzyme to support for its use as gastrointes-
tinal agents in traditional medicine. Isolated compounds
(Figure 1) were screened for urease inhibition activity
against jack bean urease, and their relative IC50 values
were depicted in Table 1.
Out of four BA’s tested for their urease inhibitory activity,
compound 4 was the only weakly active (IC50 = 85.23 ±
0.06 μM) and compound 1 (IC50 = 6.27 ± 0.03 μM) was
found to be the most potent compound, compared to the
standard inhibitor (thiourea, IC50 = 21.1 ± 0.3 μM). In this
series, compounds 2 and 3 (IC50 = 9.21 ± 0.06, 16.34 ± 0.06
μM, respectively) are exhibited remarkable inhibition to-
ward urease.
It could be seen that the dehydro-substituted compound
has stronger activity against urease than the hydroxy or
keto-substituted ones. To investigate the binding effects
between extracted BA’s and the Jack bean urease the mo-
lecular docking study was performed. The 3D binding
model of compound 1 is depicted in Figure 2.
In the binding model, carbonyl of Phe 569, Ser 567, Ile
568 and Lys 445 from B-domain of enzyme forms hydrogen
bonds with oxygen of the carboxyl moiety in compound 1.
Moreover, the compound may form hydrophobic interac-
tions with Ala 150, Leu 457, Try 474 and Try 475 of urease
(Figure 3). This potential inhibitory property possessed by
this compound, may be attributed to the above hydrogen
bonds and hydrophobic interactions.
The docking calculations also reveal that the complex
has the lower free energy of binding (-7.49 kcal/mol) com-
pared with other extracted compounds, which may also
explain the excellent inhibitory activity of it. As aifferent residue of urease enzyme active site involved in
Figure 5 Molecular docking of compound 3 and its interaction with different residue of urease enzyme active site involved in
interaction.
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pounds was also carried out, as it shown in Figures 4, 5, 6.
As it has shown, the enhanced percentage of urease
inhibitory activity of compounds 1, 2 and 4 with 60.5,
56.2 and 39.1%, respectively, compared to the structur-
ally related compound 3 (37.4%) may either be due to
the presence of methyl group and hydrophobic inter-
action of them with adjacent amino acids. This inter-
action becomes lower in the case of compound 3
because of steric factors. This phenomenon is depicted
clearly in Figure 5.
As it has shown in Figure 5, for compound 3, due to
hydrogen bonding between oxygen of carboxyl group and
Arg 368 and Gln 364, conformational locking happened,Figure 6 Molecular docking of compound 4 and its interaction
with different residue of urease enzyme active site involved in
interaction.which possibly make the approach of the compound
difficult towards the enzyme’s binding site and results
in a sharp decline in inhibitory potential as compared
to compound 4 (Figure 6). In another word, substitu-
tion at ortho position of C ring with different groups
such as hydroxyl and ketone result to diminish of the
inhibition potency. This effect explains the lower hydro-
phobic interaction between methyl group and amino
acids present at interacting site.
Besides, presence of three kinds of hydrogen bonds
formed by the carboxyl group of compound 1, two kinds
of hydrogen bonds in compound 2 and one kind in
compound 4 with respective amino acids in the hydro-
phobic pocket can explain their percent of inhibition ac-
tivity order against urease (Table 1). For compound 3,
despite the existence of four hydrogen bond’s percent of
inhibition decrease dramatically. This observation can be
explained by existing steric hindrance, which prevents
the compound to interact with the hydrophobic site
appropriately.Conclusion
In this research isolated compounds from B. carterii has
been tested against urease, which may confirm its poten-
tial traditional use for stomach problems. Based on the
above study, we can preliminarily conclude that the sub-
stituted C ring of BA’s may result to decreased inhibition
concentration compared with the reference inhibitor
thiourea. In addition, hydrophobic interactions between
methyl group of compounds and near residues play an
important role in the inhibition. This observation can be
applied to the development of new antiulcer agents.
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